Oxidative stress arises from the excessive production of toxic free radicals, known as reactive oxygen species (ROS), regularly generated as byproducts of mitochondrial ATP production.When the balance between ROS generation and antioxidant defenses, such as glutathione, is disrupted, ROS will accumulate, leading to cellular damage (1). Oxidative stress leads to lipid peroxidation of neuronal membranes, protein damage, and DNA/RNA oxidation, triggering cellular apoptosis and promoting the release of inflammatory cytokines, which play a key role in the pathogenesis of neurocognitive disorders (2). These free radicals cause neuronal protein and genetic dysfunctions, leading to protein aggregation (such as Lewy bodies, amyloid plaques, or neurofibrillary tangles) and iron accumulation in the brain-common pathological features of neurocognitive disorders like Parkinson's disease (PD), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and prion diseases (2).Smoking is a major public health concern due to its association with high morbidity and mortality. Numerous studies have demonstrated its strong correlation with cardiovascular, respiratory, and cancer-related diseases, ultimately increasing mortality rates and healthcare costs (3). However, this contrasts with extensive epidemiological research suggesting an inverse correlation between smoking and the incidence of neurodegenerative diseases like PD and AD, while not negating the higher mortality rate among smokers (4,5). This observation suggests that certain compounds in tobacco smoke may offer potential therapeutic benefits.Nicotine is the most abundant and extensively studied components of tobacco. Numerous studies have shown that neurodegenerative diseases are associated with a reduction in nicotinic acetylcholine receptors (nAChRs) (6).Upregulation. Nicotine's interaction with α7 and α4β2-nAChRs, leading to their upregulation and an increase in binding sites, may underlie its neuroprotective effects in patients with PD and AD. This mechanism could contribute to both symptomatic relief and improved cognitive function (7) . Radiological and postmortem studies have shown a reduction in nAChR density in individuals with these neurodegenerative diseases (6,8). These findings support the hypothesis that enhancing nAChR expression, may be one mechanism by which nicotine provides neuroprotection, potentially reducing or delaying disease onset.A substantial body of research has investigated the antioxidant properties of nicotine. Most of these studies are based on preclinical trials at the cellular, molecular, or animal level. However, also clinical, epidemiological, and postmortem studies in humans highlight the significant therapeutic potential of nicotine. A mechanistic biochemical representation of the major nicotine-related pathways that are thought to be involved in reducing oxidative stress is depicted in Figure 1.In 1999, Linert et al. (9) investigated the potential antioxidant actions of nicotine in both in vitro and in vivo models. They analyzed the effect of iron in the substantia nigra pars compacta when combined with hydrogen peroxide (H₂O₂) to induce the Fenton reaction, a process that amplifies oxidative stress and is considered a key mechanism underlying Parkinson's disease.Their results suggest that nicotine can bind iron and potentially reduce its redox activity; however, direct evidence for its inhibition of the Fenton reaction remains limited. Nonetheless, this interaction could represent one pathway through which nicotine exerts antioxidative and, consequently, neuroprotective effects.A study conducted by Guan et al. in 2003 (10) investigated the effects of varying concentrations of nicotine, along with oxidative and antioxidative substances, on the viability of a rat pheochromocytoma cell line. Cell survival was assessed using the MTT assay (3-(4,5methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay), a method that evaluates cellular metabolic activity based on mitochondrial function. A decrease in MTT assay readings was interpreted as indicative of cell destruction through oxidative stress mechanisms. The results demonstrated that cell viability remained stable when exposed to low concentrations of nicotine. In contrast, higher nicotine doses resulted in a reduction in cell survival. But, the coadministration of antioxidants with high nicotine doses mitigated this effect, preserving cell viability at levels comparable to control samples. Similarly, the addition of oxidative agents to the culture, combined with low-dose nicotine, maintained cell viability comparable to that of the control group. The study also explored the impact of amyloid beta peptide (Aβ25-35), a neurotoxic molecule implicated in Alzheimer's disease due to its oxidative properties.Exposure to Aβ25-35 significantly reduced cell viability; however, the administration of lowdose nicotine restored cell survival to normal levels. In contrast, increasing the nicotine dose led to a marked reduction in cell viability. These findings underscore the dual role of nicotine, with low concentrations exerting a protective effect under conditions of oxidative stress, while higher doses are cytotoxic. Dong and collaborators (11) conducted an interesting study evaluating the effect of low-dose nicotine on hippocampal neurons under the hypothesis of a protective effect against Alzheimer's disease. In their research, they demonstrated that nicotine suppresses neuronal damage induced by H₂O₂ in hippocampal cells, reducing the generation of ROS through the activation of α7-nAchR and upregulation of Erk 1 and 2 (extracellular signal-Regulated Kinases 1 and 2), essential in promoting cell survival and proliferation and prevention of apoptosis.Another recent trial conducted by Boiangiu et al (12) using rat models of AD showed that cotinine and 6-hydroxy-L-nicotine, both nicotinic derivatives, improve...